Sejong University earns global recognition, ranks third domestically
The Seoul-based university placed 238th overall, following Seoul National University and Yonsei University, which ranked 122nd and 234th, respectively.
The rankings were compiled by US News & World Report, an American publication that annually evaluates universities across 13 indicators, including research reputation, publication and citation performance, and the extent of international collaboration.
This marks the second consecutive year that Sejong has held the No. 3 position among Korean institutions in the assessment, while rising three places in the global ranking from the previous year.
Specifically, Sejong University ranked 38th globally for the proportion of top 10 percent most-cited papers, and 89th for the share of top 1 percent most-cited papers. Its level of collaboration with international institutions was also highly rated.
Sejong also earned global recognition for its academic departments, with water resources engineering ranked 35th, mathematics 51st, electrical and electronic engineering 70th, and artificial intelligence 99th.
Sejong University President Um Jong-hwa attributed the results to the university's longstanding focus on strengthening its research capacity and global engagement.
'This outcome reflects our commitment to a research-driven education model, continued investment in research, and expansion of international collaboration,' Um said.
'We will continue to grow as a leading global research university that delivers academic excellence and social contributions.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
![[Graphic News] Incheon National University ranks 9th in innovation](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F08%2F05%2Fnews-p.v1.20250805.4802979ce1e2467295cec8dab639f645_T1.gif&w=3840&q=100)
![[Graphic News] Incheon National University ranks 9th in innovation](/_next/image?url=https%3A%2F%2Fall-logos-bucket.s3.amazonaws.com%2Fkoreaherald.com.png&w=48&q=75){kind=small}
Korea Herald
a day ago
- Korea Herald
[Graphic News] Incheon National University ranks 9th in innovation
South Korea's Incheon National University has been ranked 9th in the 2025 World University Rankings for Innovation. Incheon excelled in several categories, placing 3rd in student mobility and openness, 4th in culture and values and 8th in funding for sustainability. This year's rankings considered a record 4,866 innovation programs submitted by 1,253 universities in 87 countries. The top three spots were awarded to Minerva University (US), Arizona State University (US) and Ecole 42 (France). Among Korean universities, Seoul National University and Hankuk University of Foreign Studies ranked 19th and 22nd, respectively, following Incheon.
Korea Herald
4 days ago
- Korea Herald
LG deepens biohealth push with investment in US anticancer biotech
LG Group is accelerating its push into the biohealth sector by investing in Strand Therapeutics, a US-based developer of messenger RNA-based cancer therapies. LG recently participated as a Series B investor in Strand Therapeutics through its venture capital arm, LG Technology Ventures, according to industry sources on Sunday. Headquartered in Cambridge, Massachusetts, the biopharma firm was founded in 2017 by a group of synthetic biologists from the Massachusetts Institute of Technology. The firm specializes in programming cells within the body to produce precise amounts of antigens at the right time to treat cancer, autoimmune conditions and rare diseases. With this latest investment, LG Technology Ventures' cumulative funding in biotech startups is estimated to have surpassed $50 million. The move aligns with LG's strategic emphasis on 'ABC' industries ― artificial intelligence, bio and clean tech ― as future growth engines. The conglomerate is focusing on creating cross-sector synergies by integrating advanced technologies with health care and sustainability-driven ventures. The group's Chair Koo Kwang-mo underscored the importance of AI and biotechnology in his New Year's address, saying, 'We are striving for a future where loved ones can live longer, healthier lives through breakthrough therapies.' In February, LG made a follow-up investment in ADARx Pharmaceuticals, a San Diego-based company developing first-in-class treatments for rare metabolic diseases through appetite suppression. LG has also invested in several other biohealth innovators, including: Aetion, Eko Health and Accellex. To strengthen its research and development capabilities, LG is increasingly integrating AI with biotechnology. Earlier this month, LG AI Research, the artificial intelligence arm of LG Group, unveiled Exaone Pass 2.0, an AI diagnostic model capable of identifying cancer in under one minute.
Korea Herald
22-07-2025
- Korea Herald
Ex-Celltrion veteran to head Daewoong's new biosimilar division
Korean traditional medicine powerhouse seeks new growth engine Daewoong Pharmaceutical said Tuesday that it has decided to launch a biosimilar business as the Korean traditional drug maker looks for new growth engines. Daewoong named Hong Seung-suh -- who led biosimilar R&D and global commercialization at Celltrion between 2002 and 2019, and has nearly 20 years of experience in the field -- as the head of its biosimilar business division. 'It's very meaningful that Daewoong Pharmaceutical, which has contributed to improving the health of Koreans over the last 80 years, is entering the biosimilar market,' said Hong. 'Biosimilar is a sector that can play a very important role in creating a medical environment in which anyone can receive treatment. Based on Daewoong Pharmaceutical's sales network and driving force, we will contribute to offering better accessibility to treatment for all patients in the world.' Biosimilar products, which are biologic medicines very similar to already approved reference biologics, are considered more affordable treatment options that can replace pricier drugs. As biosimilar products usually have shorter development periods and higher chances of approval compared to new drugs, they tend to reduce risk while bolstering cost competitiveness. According to global market analysts at IMARC Group, the global biosimilar market reached $26.5 billion last year and is expected to hit $185.1 billion by 2033. For its biosimilar business, Daewoong plans to not only strengthen its own development capabilities but also actively seek strategic partnerships both in Korea and overseas with other biosimilar players and contract development and manufacturing organizations, or CDMOs, as the drug maker aims to expand its product portfolio and enter major markets such as Europe and the United States in the long term to transform into a global bio company. 'As Daewoong Pharmaceutical boasts experience learned from developing a variety of medicines and commercializing them, and thanks to our global partnership capabilities, we will be able to demonstrate our distinctive ability to take action through not only self-development but also co-development in the biosimilar market,' said Park Seong-soo, CEO of Daewoong Pharmaceutical. 'Instead of being satisfied with short-term achievements, we plan to carry out our mid- to long-term strategies step-by-step with the goal of becoming an impactful player in the global market.'
